A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

NCT03292172 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

36

Enrollment

INDUSTRY

Sponsor class

Stopped Portfolio prioritization

Conditions

Advanced Ovarian Cancer
Triple Negative Breast Cancer

Interventions

DRUG: Atezolizumab
DRUG: RO6870810

Sponsor

Hoffmann-La Roche